https://www.selleckchem.com/pr....oducts/pexidartinib-
4%). Conventional TB evaluation was associated with an increase of 4.4 hospital days compared to propensity-matched controls. Xpert-based testing strategies dominated conventional TB evaluation with a cost savings of $5,947 (95% CI, $1,156-$12,54 and $4,445 (95% CI, $696-$9,526) per patient depending on the number of Xpert tests performed (1 vs 2, respectively) and assumptions about the reduction of length of stay achieved. In the evaluation of hospitalized patients for pulmonary TB, Xpert-based testing has superior diagn
Like
Comment
Share
